Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04784143 · ClinicalTrials.gov registry record · Phase 2
Study Comparing Two Versus Three Active MDMA-assisted Sessions in U.S. Military Veterans With Chronic PTSD
A Phase 2 study, sponsored by Resilient Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT04784143: Clinical Trial Phase 2 study, sponsored by Resilient Pharmaceuticals.
NCT04784143 is a Phase 2 study that was terminated before completion, run by Resilient Pharmaceuticals. The registered enrollment target is 26 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04784143, a Phase 2 study, was terminated before completion, sponsored by Resilient Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn if MDMA-assisted therapy is effective in U.S. military veterans with at least moderate chronic PTSD. The main question it aims to answer is: Are two versus three MDMA-assisted therapy sessions in an outpatient treatment clinic more effective? Researchers will compare two MDMA-assisted therapy sessions to three MDMA-assisted therapy sessions. Participants will undergo three non-drug preparatory sessions prior to their first MDMA-assisted therapy session. Each MDMA-assisted therapy session will be followed by three non-drug integrative therapy sessions.
Interventions
- BEHAVIORAL Psychotherapy
- DRUG Midomafetamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2021-11-08 |
| Est. Completion | 2024-06-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04784143
The ClinicalTrials.gov registry entry for NCT04784143 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Resilient Pharmaceuticals, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Psychotherapy is the first listed.
NCT04784143 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04784143 about?
NCT04784143 is a clinical study titled "Study Comparing Two Versus Three Active MDMA-assisted Sessions in U.S. Military Veterans With Chronic PTSD". The goal of this clinical trial is to learn if MDMA-assisted therapy is effective in U.S. military veterans with at least moderate chronic PTSD. The main question it aims to answer is: Are two versus three MDMA-assisted therapy sessions in an outpatient treatment clinic more effective? Researchers ...
What is the current status of trial NCT04784143?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2021-11-08. Estimated completion is 2024-06-27.
What interventions are being tested in trial NCT04784143?
The interventions under investigation include: Psychotherapy (BEHAVIORAL), Midomafetamine (DRUG).
Who is sponsoring clinical trial NCT04784143?
This trial is sponsored by Resilient Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.